000022346 000__ 03297cam\a2200541\i\4500
000022346 001__ 22346
000022346 003__ SzGeWIPO
000022346 005__ 20210318104857.0
000022346 008__ 980910s1998\\\\enka\\\\rbj\\\001\0\eng\\
000022346 020__ $$a9041106987
000022346 020__ $$z9789041106988
000022346 035__ $$a(wipo)(CD )98-1368
000022346 035__ $$a(OCoLC)41238450
000022346 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000022346 043__ $$an-us---
000022346 050_4 $$aKF3133.B56$$bD83 1998
000022346 08204 $$a346.730486$$221
000022346 084__ $$aG 252 DUC.P
000022346 090__ $$c24270$$d24270
000022346 1001_ $$aDucor, Philippe Georges,$$eauthor.
000022346 24510 $$aPatenting the recombinant products of biotechnology /$$cby Philippe Georges Ducor.
000022346 264_1 $$aLondon :$$bKluwer Law International,$$c1998.
000022346 300__ $$axvii, 179 pages :$$billustrations ;$$c25 cm
000022346 336__ $$atext$$btxt$$2rdacontent
000022346 337__ $$aunmediated$$bn$$2rdamedia
000022346 338__ $$avolume$$bnc$$2rdacarrier
000022346 500__ $$aPrice : 51.52; Inv.# CH52902; Date 11/08/98; Supplier : CroftHouse, UK; Recd 25/08/98; Contents : 1. Patent law primer; 2. Recombinant products and the standard for obviousness : a typology; 3. In re Deuel : the Federal circuit and "translation" DNAs; 4. Generalization of a concept : other biotechnology products are "translation" inventions; 5. Consequences and remedies;.
000022346 500__ $$a"Originally presented as the author's thesis presented at Stanford University School of Law for the J.S.D degree"--Preface.
000022346 500__ $$aOmslagtitel: Patenting the recombinant products of biotechnology and other molecules.
000022346 500__ $$aUmschlagtitel: Patenting the recombinant products of biotechnology and other molecules.
000022346 504__ $$aIncludes bibliographical references (pages 167-172) and index.
000022346 520__ $$aThis work examines the requirements for patentability in the context of biotechnology, with a special focus on non obviousness. Reviewing the relevant case law, it analyses thoroughly non obviousness as applied to biotechnology molecular products. It first offers a typology of recombinant inventions, useful in determining ultimate non obviousness and patentability. Three categories of recombinant products are distinguished. "Translation" inventions, obtained by entering a known molecular information into a known process. "Molecular modification" products, obtained by modifying prior art molecules. "Combination" inventions, obtained by combining several known functional molecular units. Recognizing that many "translation" inventions are at risk of being considered obvious upon maturation of the underlying technology, the author examines possible alternatives for protection.
000022346 650_0 $$aBiotechnology$$zUnited States.
000022346 650_0 $$aRecombinant DNA$$vPatents.
000022346 650_0 $$aPatent laws and legislation.
000022346 650_0 $$aPatents$$zUnited States.
000022346 650_0 $$aBiotechnology industries$$xLaw and legislation$$zUnited States.
000022346 650_0 $$aPatent laws and legislation$$zUnited States.
000022346 650_4 $$aPATENTS : BIOTECHNOLOGY
000022346 650_4 $$aMOLECULAR BIOTECHNOLOGY PRODUCTS
000022346 650_4 $$aBIOTECHNOLOGY : PATENT LAW
000022346 651_0 $$aUnited States$$xCommerce$$xLaw and legislation.
000022346 655_7 $$aPatents.$$2lcgft
000022346 7001_ $$aDucor, Phillipe G.
000022346 903__ $$v1
000022346 942__ $$cMON
000022346 952__ $$w2006-11-03$$p1998-1368$$r0.00$$u34939$$bMAIN$$10$$kG 252 DUC.P$$v1998-08-26$$ztagged$$71
000022346 980__ $$aBIB
000022346 999__ $$c24270$$d24270